Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vinblastine 抑制微管形成并抑制 nAChR 活性,IC50 为 8.9 μM,用于治疗某些类型的癌症。 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Vinblastine sulfate 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 391 | 待询 | ||
10 mg | ¥ 705 | 待询 | ||
25 mg | ¥ 1,268 | 待询 | ||
50 mg | ¥ 2,294 | 待询 | ||
100 mg | ¥ 3,620 | 待询 | ||
200 mg | ¥ 6,516 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 705 | 待询 |
Vinblastine 的其他形式现货产品:
产品描述 | Vinblastine inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM, used to treat certain kinds of cancer. |
靶点活性 | nAChR:8.9 μM |
体外活性 | Vinblastine does not depolymerize spindle microtubules, yet it powerfully blocks mitosis (for example, IC50 0.8 nM in HeLa cells) and cells die by apoptosis[2]. In NB4 cells, vinblastine produces alteration of p53 and DNA fragmentation. Vinblastine treatment has an antiproliferative effect via the induction of apoptosis producing Bax/Bcl-2 imbalance. Vinblastine treatment suppresses NFκB expression and depresses NFκB-DNA binding activity while maintaining JNK activation that subsequently results in apoptotic response through caspase-dependent pathway[3]. Vinblastine is found to trigger apoptosis as evidenced by the loss of mitochondrial membrane potential, the release of both cytochrome c and apoptosis inducing factor, activation of caspase-9 and 3, and cleavage of Poly (ADP-ribose)-Polymerase[4]. |
体内活性 | Vinblastine is a widely used anticancer drug with undesired side effects. Its conjugation with carrier molecules could be an efficient strategy to reduce these side effects[5]. |
细胞实验 | Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth. (Only for Reference) |
分子量 | 810.97 |
分子式 | C46H58N4O9 |
CAS No. | 865-21-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 6 mg/mL (7.39 mM)
DMSO: 42 mg/mL
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 1.2331 mL | 6.1655 mL | 12.3309 mL | 30.8273 mL |
5 mM | 0.2466 mL | 1.2331 mL | 2.4662 mL | 6.1655 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Vinblastine 865-21-4 Cytoskeletal Signaling Neuroscience AChR Microtubule Associated Inhibitor inhibitor inhibit